Summary
In two separate studies of patients with ovarian cancer, subjects were treated on a protocol comprising 400 mg/m2 carboplatin in combination with 1 g/m2 cyclophosphamide (group A) or 5 g/m2 ifosfamide with mesna (group B). The dose intensities achieved in group A were 87.2 mg/m2 carboplatin per week and 245.8 mg/m2 cyclophosphamide per week (34 patients). In group B, the dose intensities achieved were 124.1 mg/m2 carboplatin per week and 2,020 mg/m2 ifosfamide per week (25 patients). Two formulae for the prediction of the optimal dose of carboplatin based on renald function and degree of myelosuppression are compared with that based on surface area, and that recently proposed by Calvert is recommended. The importance of dose intensity and the total dose delivered in phase II and III studies is emphasized.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts D, Mason N, Surwit E, Weiner S, Hammond N, Deppe G (1985) Phase I trial of carboplatin-cyclophosphamide and iproplatincyclophosphoamide in advanced ovarian cancer: a Southwest Oncology Group study. Cancer Treat Rev 12 [Suppl A]: 83–92
Bramwell VHC,Mourdisen HT, Santoro A, Blackledge G, Somers K, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, Van Oosterom A (1987) Cyclophosphamide versus ifosfamide: final report of a randomised phase III trial in aduls soft tissue sarcoma. Eur J Cancer Clin Oncol 23: 311
Calvert AH, Harland SJ, Newell DR, Siddick ZH, Harrap KR (1985) Phase I studies with carboplatin at the Royal Marsden Hospital Cancer Treat Rev 12 [Suppl A]: 51–57
Calvert AH, Newell DR, Gumbrell LA, Boxall FE, Eeles RA, Horwich A (1989) The clinical pharmacokinetics of carboplatin: prospective validation of a dosage formula for use in high dose single agent and combination studies. Proc Am Soc Clin Oncol abstr. 271
Dembo AJ (1987) Time-dose factors in chemotherapy: expanding the concept of dose intensity. J Clin Oncol 5: 694–696
Egorin MJ, Van Echo DA, Ohran EA (1985) Prospective validation of a pharmacologically based dosing scheme for thecis-diamminedichloroplatinum analogue diaminocyclobutane dicarboxylatoplatinum. Cancer Res 45: 6502–6505
Fish RG, Adams M, Shelly M, Kerby I, Johanse K, Rocker I (1987) A simplified dosing scheme for carboplatin. Proc 4th Eur Conf Clin Oncol 215, abstr. 818
Foster BJ, Clagett-Carr K, Leyland-Jones B, Hoth D (1985) Results of NCl-sponsored phase I trials with carboplatin. Cancer Treat Rev 12 [Suppl A]: 43–49
Grollman A (1929) Physiologic variation in the cardiac output of man: VI. The value of the cardiac output of the normal individual in the basal, resting condition. Am J Physiol 90: 210–217
Hrynuik W, Bush A (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1289
Levin L, Hrynuik WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756–757
Monfardini S, Renard J Pinedo HM, Cavalli F, Van Glabbeke M (1986) Iproplatin (CHIP)- and carboplatin (CBCA)- induced thrombocytopenia: analysis of risk factors. Proc Am Assoc Cancer Res 654 (27): 165 abstr. 654
Vriesendorp HM (1985) Optimal prescription method for cancer chemotherapy. Semin Haematol 13 [Suppl 16]: 57–63
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Green, J.A., Smith, K. Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide. Cancer Chemother. Pharmacol. 26 (Suppl 1), S22–S25 (1990). https://doi.org/10.1007/BF00685411
Issue Date:
DOI: https://doi.org/10.1007/BF00685411